APA (7th ed.) Citation

Neyns, B., Dirven, I., Lescrauwaet, L., Cammaert, M., Geens, W., Geeraerts, X., . . . Duerinck, J. (2024). 441O A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG). Annals of Oncology, 35, S406. https://doi.org/10.1016/j.annonc.2024.08.511

Chicago Style (17th ed.) Citation

Neyns, B., et al. "441O A Phase I Clinical Trial on the Intracranial Administration of Autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ Myeloid Dendritic Cells (myDC) in Combination with Ipilimumab (IPI) and Nivolumab (NIVO) in Patients with Recurrent High-grade Glioma (rHGG)." Annals of Oncology 35 (2024): S406. https://doi.org/10.1016/j.annonc.2024.08.511.

MLA (9th ed.) Citation

Neyns, B., et al. "441O A Phase I Clinical Trial on the Intracranial Administration of Autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ Myeloid Dendritic Cells (myDC) in Combination with Ipilimumab (IPI) and Nivolumab (NIVO) in Patients with Recurrent High-grade Glioma (rHGG)." Annals of Oncology, vol. 35, 2024, p. S406, https://doi.org/10.1016/j.annonc.2024.08.511.